Methods and compositions for attenuated chlamydia as vaccine and vector
AssigneeBoard of Regents, The University of Texas System
InventorGuangming Zhong
Life of this patent
Estimating the term…
Abstract
The present invention provides Chlamydia organisms and compositions and methods of use in the treatment/prevention of chlamydial infection in a subject, for eliciting an immune response in a subject and for use as vectors.
Claims26
An isolated Chlamydia trachomatis cell comprising
- a) a substitution at Q117 in open reading frame CT849, wherein said amino acid numbering is based on the amino acid sequence of SEQ ID NO:1;
- and
- b) a G216* mutation and/or a substitution at G322 in open reading frame CT389, wherein said amino acid numbering is based on the amino acid sequence of SEQ ID NO:2,
- wherein said Chlamydia trachomatis cell has a phenotype due to said substitution of (a) and said mutation and/or substitution of (b) of attenuated pathogenicity.
A method of delivering a heterologous nucleic acid molecule to a GI tract of a subject, comprising administering to the GI tract of the subject a Chlamydia trachomatis cell that does not comprise a) a substitution at Q117 in open reading frame CT849, wherein said amino acid numbering is based on the amino acid sequence of CT849 as provided herein as SEQ ID NO:1;
- and b) a G216* mutation and/or a substitution at G322 in open reading frame CT389, wherein said amino acid numbering is based on the amino acid sequence of CT389 as provided herein as SEQ ID NO:2 and that comprises a heterologous nucleic acid molecule.
A method of inducing an immune response in the GI tract of a subject, comprising administering to the subject a Chlamydia trachomatis cell comprising a) a substitution at Q117 in open reading frame CT849, wherein said amino acid numbering is based on the amino acid sequence of CT849 as provided herein as SEQ ID NO:1;
- and b) a G216* mutation and/or a substitution at G322 in open reading frame CT389, wherein said amino acid numbering is based on the amino acid sequence of CT389 as provided herein as SEQ ID NO:2, thereby inducing an immune response to the Chlamydia trachomatis cell in the GI tract of the subject.
A method of inducing an immune response in the GI tract of a subject, comprising administering to the subject a Chlamydia trachomatis cell that does not comprise a) a substitution at Q117 in open reading frame CT849, wherein said amino acid numbering is based on the amino acid sequence of CT849 as provided herein as SEQ ID NO:1;
- and b) a G216* mutation and/or a substitution at G322 in open reading frame CT389, wherein said amino acid numbering is based on the amino acid sequence of CT389 as provided herein as SEQ ID NO:2, thereby inducing an immune response to the Chlamydia trachomatis cell in the GI tract of the subject.
An isolated CT389 polypeptide comprising a G216* nonsense mutation and/or a substitution at G322 in open reading frame CT389, wherein said amino acid numbering is based on the amino acid sequence of CT389 as provided herein as SEQ ID NO:2.
Dependencies are inferred from the claim text.